pharmaceutical-investing Revive Therapeutics Provides Corporate Update on its Pharmaceutical Initiatives
pharmaceutical-investing Revive Therapeutics Provides an Update on its Psilocybin-Based Pharmaceutical Program
pharmaceutical-investing Revive Therapeutics Announces U.S. FDA Recommendation to Proceed Directly Into A Phase 3 Confirmatory Clinical Trial
pharmaceutical-investing Revive Therapeutics Announces Research Partnership Agreement with the University of Wisconsin-Madison
pharmaceutical-investing Revive Therapeutics Partners with Complete Phytochemical Solutions to Advance Research Initiatives for Psilocybin-Based Pharmaceutical Products
pharmaceutical-investing Revive Therapeutics Announces Closing of Second Tranche of Brokered Private Placement
pharmaceutical-investing Revive Therapeutics Engages Novotech as Asia-Pacific CRO for Bucillamine in the Treatment of Infectious Diseases
Revive Therapeutics Explores the use of Bucillamine as a Novel Treatment for Infectious Diseases Including COVID-19
Revive Provides Update on its Clinical Development Plan for Cannabidiol in the Treatment of Autoimmune Hepatitis
